Run domain Beclin-1-interacting and cysteine-rich domain-containing protein (Rubicon) (RUBCN)

Rubicon (Run domain Beclin-1-interacting and cysteine-rich domain-containing protein) is a critical negative regulator of canonical autophagy and endocytic trafficking. It primarily functions by interacting with the Class III phosphatidylinositol 3-kinase (PI3K) complex and the small GTPase Rab7 to inhibit autophagosome maturation and autophagosome-lysosome fusion. Interestingly, Rubicon plays a paradoxical role as a positive regulator of non-canonical autophagy processes, such as LC3-associated phagocytosis (LAP) and LC3-associated endocytosis (LANDO), which are vital for pathogen clearance and immune homeostasis. Rubicon is an emerging therapeutic target because its expression levels increase significantly with age across species, contributing to the age-related decline in autophagic flux. Suppression of Rubicon has been shown to extend lifespan and ameliorate age-associated pathologies like kidney fibrosis and neurodegeneration in model organisms. Conversely, loss-of-function mutations in the RUBCN gene are associated with Spinocerebellar ataxia autosomal recessive 15 (SCAR15), and the protein is implicated in metabolic disorders like nonalcoholic fatty liver disease (NAFLD). Therapeutic development currently focuses on small molecule inhibitors and peptides, such as TIPTP, which aim to selectively disrupt Rubicon’s inhibitory functions to restore autophagic activity and reduce inflammation.

Other names

RUBCNKIAA0226BaronBeclin-1 associated RUN domain containing proteinRubicon autophagy regulatorSCAR15

Inhibition of Rubicon-mediated suppression to activate canonical autophagy or disruption of the Rubicon-p22phox axis to modulate inflammatory ROS production